Table 4 Association between characteristics of trials and statistically significant outcome or conclusions favoring the test drug: Multivariate logistic regression (first/main reports only, n = 115)
| Â | Â | Results Favor Test Drug | Conclusions Favor Test Drug | ||||
|---|---|---|---|---|---|---|---|
Characteristic | Category | Favorable n/Total n (%) | OR (95% CI) | P | Favorable n/Total n (%) | OR (95% CI) | P |
Trial registration before publication | No | 34/70 (49) | 1.00 | Â | 46/70 (66) | 1.00 | Â |
| Â | Yes | 28/45 (62) | 1.11 (0.44-2.80) | 0.832 | 34/45 (76) | 1.10 (0.41-2.98) | 0.854 |
Blinding | Stringent | 13/31 (42) | 1.00 | Â | 20/31 (65) | 1.00 | Â |
| Â | Not stringent | 49/84 (58) | 3.03 (1.13-8.16) | 0.028 | 60/84 (71) | 1.86 (0.69-5.05) | 0.221 |
Sample size | Natural log | - | 2.20 (1.40-3.45) | <0.001 | - | 1.65 (1.09-2.51) | 0.019 |
Comparison group | Active comparator | 24/51 (47) | 1.00 | Â | 33/51 (65) | 1.00 | Â |
| Â | Placebo | 38/64 (59) | 2.33 (0.89-6.07) | 0.084 | 47/64 (73) | 1.98 (0.73-5.41) | 0.182 |
Primary efficacy outcome | Survival | 14/25 (56) | 1.00 | Â | 17/25 (68) | 1.00 | Â |
| Â | Surrogate | 48/90 (53) | 2.76 (0.82-9.28) | 0.102 | 63/90 (70) | 2.86 (0.80-10.18) | 0.105 |
Sponsored | No | 13/27 (48) | 1.00 | Â | 15/27 (56) | 1.00 | Â |
| Â | Yes | 49/88 (56) | 1.02 (0.37-2.84) | 0.965 | 65/88 (74) | 1.94 (0.71-5.29) | 0.194 |